RecruitingNot Applicable

Determining the Mechanisms of Loss of CAR T Cell Persistence

United Kingdom50 participantsStarted 2023-10-18

Plain-language summary

A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.

Who can participate

Age range25 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel)
✓. Written informed consent

Exclusion criteria

✕. Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial
✕. Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol

What they're measuring

Time to circulating CAR-T cell loss

Timeframe: Through study completion, until the last patient reaches 1 year post-infusion

Trial details

NCT IDNCT05809284

SponsorUniversity College, London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-01

Contact for this trial

CARPERS Trial Manager

442031084189 ctc.carpers@ucl.ac.uk

View on ClinicalTrials.gov More Acute Lymphoblastic Leukemia With Failed Remission trials